Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
Conclusion:
Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC patients that would favorably respond to a combination of olaparib with SAHA. This provides a strong rationale for treating TNBC patients with PTEN expression with a combination therapy consisting of olaparib and SAHA.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Ahrum MinSeock-Ah ImDebora KimSang-Hyun SongHee-Jun KimKyung-Hun LeeTae-Yong KimSae-Won HanDo-Youn OhTae-You KimMark O¿ConnorYung-Jue Bang Source Type: research